These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 28380046)

  • 21. Discovery of GPCR Ligands by Molecular Docking Screening: Novel Opportunities Provided by Crystal Structures.
    Rodríguez D; Ranganathan A; Carlsson J
    Curr Top Med Chem; 2015; 15(24):2484-503. PubMed ID: 26126906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A benchmarking study on virtual ligand screening against homology models of human GPCRs.
    Lim VJY; Du W; Chen YZ; Fan H
    Proteins; 2018 Sep; 86(9):978-989. PubMed ID: 30051928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterizing common substructures of ligands for GPCR protein subfamilies.
    Erguner B; Hattori M; Goto S; Kanehisa M
    Genome Inform; 2010; 24():31-41. PubMed ID: 22081587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Structural Framework for GPCR Chemogenomics: What's In a Residue Number?
    Vass M; Kooistra AJ; Verhoeven S; Gloriam D; de Esch IJP; de Graaf C
    Methods Mol Biol; 2018; 1705():73-113. PubMed ID: 29188559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interacting with GPCRs: Using Interaction Fingerprints for Virtual Screening.
    Lenselink EB; Jespers W; van Vlijmen HW; IJzerman AP; van Westen GJ
    J Chem Inf Model; 2016 Oct; 56(10):2053-2060. PubMed ID: 27626908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GPCR Homology Model Generation for Lead Optimization.
    Tautermann CS
    Methods Mol Biol; 2018; 1705():115-131. PubMed ID: 29188560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular interaction fingerprint approaches for GPCR drug discovery.
    Vass M; Kooistra AJ; Ritschel T; Leurs R; de Esch IJ; de Graaf C
    Curr Opin Pharmacol; 2016 Oct; 30():59-68. PubMed ID: 27479316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Applying Structure-Based Drug Design Approaches to Allosteric Modulators of GPCRs.
    Congreve M; Oswald C; Marshall FH
    Trends Pharmacol Sci; 2017 Sep; 38(9):837-847. PubMed ID: 28648526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural basis for ligand binding and specificity in adrenergic receptors: implications for GPCR-targeted drug discovery.
    Huber T; Menon S; Sakmar TP
    Biochemistry; 2008 Oct; 47(42):11013-23. PubMed ID: 18821775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ligand and decoy sets for docking to G protein-coupled receptors.
    Gatica EA; Cavasotto CN
    J Chem Inf Model; 2012 Jan; 52(1):1-6. PubMed ID: 22168315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative Analysis of QSAR-based vs. Chemical Similarity Based Predictors of GPCRs Binding Affinity.
    Luo M; Wang XS; Tropsha A
    Mol Inform; 2016 Jan; 35(1):36-41. PubMed ID: 27491652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigating Small-Molecule Ligand Binding to G Protein-Coupled Receptors with Biased or Unbiased Molecular Dynamics Simulations.
    Marino KA; Filizola M
    Methods Mol Biol; 2018; 1705():351-364. PubMed ID: 29188572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PREDICT modeling and in-silico screening for G-protein coupled receptors.
    Shacham S; Marantz Y; Bar-Haim S; Kalid O; Warshaviak D; Avisar N; Inbal B; Heifetz A; Fichman M; Topf M; Naor Z; Noiman S; Becker OM
    Proteins; 2004 Oct; 57(1):51-86. PubMed ID: 15326594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure-based virtual screening of MT2 melatonin receptor: influence of template choice and structural refinement.
    Pala D; Beuming T; Sherman W; Lodola A; Rivara S; Mor M
    J Chem Inf Model; 2013 Apr; 53(4):821-35. PubMed ID: 23541165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bridging Crystal Engineering and Drug Discovery by Utilizing Intermolecular Interactions and Molecular Shapes in Crystals.
    Spackman PR; Yu LJ; Morton CJ; Parker MW; Bond CS; Spackman MA; Jayatilaka D; Thomas SP
    Angew Chem Int Ed Engl; 2019 Nov; 58(47):16780-16784. PubMed ID: 31385643
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Approaches for Differentiation and Interconverting GPCR Agonists and Antagonists.
    Miszta P; Jakowiecki J; Rutkowska E; Turant M; Latek D; Filipek S
    Methods Mol Biol; 2018; 1705():265-296. PubMed ID: 29188567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. G-protein-coupled receptor-focused drug discovery using a target class platform approach.
    Heilker R; Wolff M; Tautermann CS; Bieler M
    Drug Discov Today; 2009 Mar; 14(5-6):231-40. PubMed ID: 19121411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Virtual screening of GPCRs: an in silico chemogenomics approach.
    Jacob L; Hoffmann B; Stoven V; Vert JP
    BMC Bioinformatics; 2008 Sep; 9():363. PubMed ID: 18775075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ligand Discovery for a Peptide-Binding GPCR by Structure-Based Screening of Fragment- and Lead-Like Chemical Libraries.
    Ranganathan A; Heine P; Rudling A; Plückthun A; Kummer L; Carlsson J
    ACS Chem Biol; 2017 Mar; 12(3):735-745. PubMed ID: 28032980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimal strategies for virtual screening of induced-fit and flexible target in the 2015 D3R Grand Challenge.
    Ye Z; Baumgartner MP; Wingert BM; Camacho CJ
    J Comput Aided Mol Des; 2016 Sep; 30(9):695-706. PubMed ID: 27573981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.